Clinical Trials Logo

Non-hodgkin Lymphoma,B Cell clinical trials

View clinical trials related to Non-hodgkin Lymphoma,B Cell.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04094142 Completed - Clinical trials for Non-hodgkin Lymphoma,B Cell

Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Start date: July 9, 2019
Phase: Phase 2
Study type: Interventional

NCCN guidelines for B cell lymphoma suggest that patients with relapsed/refractory aggressive NHL who are candidate for high-dose therapy should receive combination of cytotoxic chemotherapies as 2nd line treatment. However, proportion of patients who are adequately salvaged by second line chemotherapy and high-dose chemotherapy with stem cell rescue is unsatisfactory. Moreover, many fragile patients are unfit for salvage cytotoxic chemotherapy and/or high-dose chemotherapy. Hence, most of patients with relapsed/refractory aggressive B-cell NHL is ultimately candidate for less-cytotoxic drugs with targeted approach. This trial is phase II trial of acalabrutinib in combination with rituximab and lenalidomide for these patients.